AUTHORS' REPLY: First, the Food and Drug Administration's (FDA's) recently publishedguidance document on adverse events states:"Typical reasons to suspect causality for an event include (I) timing of onset or termination with respect to drug use, (2) plausibility in light of a drug's known pharmacology,(3) occurrenceat a frequency above that expected in the treated population, and (4) occurrence of an event typicalof druginduced adverse reactions." Consider these reasons in the fatalities that followed mifepristoneuse: (I) all of the deaths occurred within7 days of taking mifepristone, (2) mifepristone-induced suppression of the innate immune system is plausible.' and (3) the frequency of fatalities from Clostridium sordelliiafter mifepristonefar exceeds the frequency of this infectionprior to mifepristoneavailability. Based on the FDA's guidance, there are multiplereasons to infer a causal link between mifepristone and these deaths.
Second, we believe that pregnancy is in most instances a benign, selflimited condition as evidenced by the statistic cited by Hausknecht: 99992.9/100 000 women survive pregnancy.
Third, the clinical picture of medically induced abortion can mimic the symptoms of ectopic pregnancy. If these symptoms are incorrectly ascribed to the medical abortion, then delay in diagnosis of the ectopic pregnancy can be lethal. This contraindication to the use of mifepristone has been acknowledgedby Danco Laboratories.' Fourth, given the incomplete nature of the Medwatch adverse event report (AER) 3943786-2,4 we believe our assessment remains plausible. While acetaminophen overdose can be associated with hepatic toxicity, renal failure,and disseminatedintravascular coagulation,it is also plausible that this scenario is caused by sepsis with multiorgan failure. Hausknecht infers causality from empty pill bottles but has left out crucial information in his depiction of both the adverse event and its AER. In his letter,he states that the event was related to drug overdose with alcohol. Rather, this AER stated that "current thinking was that this event was related to some sort of drug overdose (Tylenol)" and does not mention alcohol toxicity. One of the cases of fatal mifepristone-associated sepsis syndrome also had no evidence of infection initially, then progressed rapidly to multiorgan failure and death.' Hausknecht's assertion that "there are many similar errors of omission and exaggeration" is incorrect. Our review was based on the limited informationavailable in the reports submitted to the FDA by Hausknecht.
Finally, this AER illustrates the lack of documentation provided by Danco. The Medwatch AER 3943786-2 containedno emergencydepart-ment records, no hospital records, and no white blood cell count or acetaminophen levels," The report appears to reflect an initialconversation between the reporting physician and Danco but the report language is Danco's, It is curious that such an opportunity failed to produce a detailed, clear summary of the hospital course and laboratory findings or even a final diagnosis. It is the ethical responsibility of Danco to seek complete and accurate documentation for these AERs. Failure to do so thwarts postmarkctingsafety monitoring. information regarding 2 additional therapies to treat a)-antitrypsin deficiency, a genetic disease. These therapies have been welcomed in the "alpha-I community" as new options for a growing populationof newly diagnosed patients. However, we would like to provide some clarification regardingspecificactivity,purity,and functional activity.
DonnaJ Harrison MD
Specific activity, as labeled in the product insert, refers to the release specificationfor the product of each manufacturer.t" Each lot must meet that minimum specification. In the case of Aralast, the package insert lists the specific activity as not less than 0.55. 2 In August 2005, an analysis was completed by Baxter Healthcare to examine the manufacturing process for Aralast with regard to overall protein concentration, a.-protease inhibitorconcentration,and specific activity.The analysis included Aralast manufacturing data from October 2002 through October 2004, which consisted of 148 manufacturinglots. The mean ± SD total protein content was 21.6 ± 2.4 mglmL, with a mean a.-protease inhibitor concentration of 21.3 ± 1.7 mglmL. Mean specific activity is derived from
